Abstract:Background Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of tumor-related death, so it is urgently needed to discover efficient markers and targets for therapy. β-1,3- N -acetylgalactosaminyltransferase II (B3GALNT2) belongs to the β-1,3-glycosyltransferases (b3GT) family and has been reported to regulate development of both normal and tumor tissues. However, studies on the functions of B3GALNT2 in cancer are quite limited. Here we investigated the potential role of B3GALNT2 in HCC progression. Methods Western blot, qPCR, and immunohistochemistry assays were performed to quantify the relative expression of B3GALNT2 in HCC. The functions of B3GALNT2 in tumor progression were evaluated in HCC cell lines and nude mice. Metabolomics analysis was applied to detect alternatively expressed small molecules. Enzyme activity assays were employed to determine the tautomerase activity of macrophage inhibitory factor (MIF). Results For expression analysis, higher levels of B3GALNT2 were observed in tumor tissues compared with adjacent normal tissues, and upregulation of B3GALNT2 correlated with increased tumor size and worse overall survival. Changing levels of B3GALNT2 did not influence cell viability in vitro but promoted tumor growth via enhancing macrophage recruitment in vivo. Furthermore, acetoacetate was identified as a key molecule in B3GALNT2-mediated macrophage recruitment. Mechanistically, B3GALNT2 downregulated expression of enzymes involved in acetoacetate-related metabolism, and reduction of acetoacetate revived MIF activity, thus promoting macrophage recruitment. Conclusions This study evaluated B3GALNT2 as a tumor marker in HCC and revealed functions of B3GALNT2 in metabolic transformation and microenvironmental remodeling in HCC. Mechanistically, B3GALNT2 reduced expression of some metabolic enzymes and thus downregulated levels of secreted acetoacetate. This relieved the activity of MIF and enhanced macrophage recruitment to promote tumor growth.

Determination of N-acetylglucosaminyltransferase III, IV and V Activity in Extrahepatic Cholangiocarcinoma

Alteration in N-Acetylglucosaminyltransferase Activities and Glycan Structure in Tissue and Bile Glycoproteins from Extrahepatic Bile Duct Carcinoma

Primary Studies on the Changes of Structures of Sugar Chains and the Mechanisms of N-acetylglucosaminyl-transferase(GnT) in Cholangiocarcinoma Bile

Correlation of Glycosyltransferases Mrna Expression in Extrahepatic Bile Duct Carcinoma with Clinical Pathological Characteristics.

Diagnostic Value of Glypican-3, Arginase-1 and Hepatocyte Paraffin Antigen -1 in Differentiating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma

Alteration of N-acetylglucosaminyltransferases in Pancreatic Carcinoma

Expression of pGSK-3α/β (Tyr279/216) and XIAP proteins in cholangiocarcinoma and their clinical significance

Changes Inn-Acetylglucosaminyltransferase III, IV and V in Renal Cell Carcinoma

N-acetylglucosaminyltransferase V Activity in Metastatic Models of Human Hepatocellular Carcinoma in Nude Mice.

Expression and clinical significance of GS,E-cadherin and β-catenin in hepatocellular carcinoma

Serum Mucin 3A As a Potential Biomarker for Extrahepatic Cholangiocarcinoma.

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

Elevation of Serum Γ-Glutamyltransferase As a Predictor of Aggressive Tumor Behaviors and Unfavorable Prognosis in Patients with Intrahepatic Cholangiocarcinoma

Prognostic significance of β1,6-N-acetylglucosaminyltransferase V expression in patients with hepatocellular carcinoma

Reduced N-acetylglucosaminyltransferase III Expression Via Smad3 and Erk Signaling in TGF-β1-induced HCC EMT Model.

Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.

Model Based on Alkaline Phosphatase and Gamma-Glutamyltransferase for Gallbladder Cancer Prognosis

Clinical and prognostic implications of β1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer.

Increased B3GALNT2 in Hepatocellular Carcinoma Promotes Macrophage Recruitment Via Reducing Acetoacetate Secretion and Elevating MIF Activity

Changes in terminal sialyl residues linked to N-glycans in the tissue of bile duct carcinoma and bile glycoproteins

GCNT3 regulated MUC13 to promote the development of hepatocellular carcinoma through the GSK3β/β-catenin pathway